Patent intelligence · US
US 7638550
Pyrrolic derivatives with histone deacetylase inhibitory activity
Pyrrolic derivatives with histone deacetylase inhibitory activity
Patent details — US 7638550
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 29, 2009
- Expiration
- Dec 24, 2029
- Claims
- 20
- CPC classes
- A61P, A61P35/00, A61P43/00
Quick answer
US 7638550 (Pyrrolic derivatives with histone deacetylase inhibitory activity) is held by Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO). Status: granted. Granted Dec 29, 2009. Expires Dec 24, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P35/00, A61P43/00
More from Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO)
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted -
US 11813278
Highly active compounds against COVID-19
granted
Frequently asked questions
What is US patent 7638550?
US 7638550 (Pyrrolic derivatives with histone deacetylase inhibitory activity) is held by Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO). Status: granted. Granted Dec 29, 2009. Expires Dec 24, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7638550?
Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 7638550 expire?
Our index shows an expiration date of Dec 24, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.